Clinical Trials
3
Active:0
Completed:3
Trial Phases
2 Phases
Phase 2:2
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 3
1 (33.3%)Safety and Efficacy Study of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients With a Chalazion
Phase 3
Completed
- Conditions
- Chalazion
- Interventions
- Drug: Placebo TDSDrug: SUN-131 1.5% TDS
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Senju USA, Inc.
- Target Recruit Count
- 263
- Registration Number
- NCT03248440
- Locations
- 🇺🇸
SUN-131-03 Investigational Site, Racine, Wisconsin, United States
Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion
Phase 2
Completed
- Conditions
- Chalazion
- Interventions
- Drug: SUN-131 1.5% TDSDrug: Placebo TDS
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Senju USA, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02338648
- Locations
- 🇺🇸
WCCT Global Ophthalmology Research, Santa Ana, California, United States
🇺🇸Corneal Consultants of Colorado, P.C., Littleton, Colorado, United States
🇺🇸George Washington University Medical Faculty Association, Washington, D.C., District of Columbia, United States
Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Phase 2
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Senju USA, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT00836485
- Locations
- 🇺🇸
Ora, Andover, Massachusetts, United States
News
No news found